Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Wolff

Showing results (611-620 of 831) with videos related to

Pageof 84
Sort By:
Evidence-Based Practice in Child and Adolescent Mental Health|December 25, 2025
Informing Suicide Risk Assessment Practices of High-Risk Preteens: Qualitative Insights from Youth and CaregiversKatherine M Tezanos, Elizabeth K Reynolds, April R Highlander, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2012
Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancerBryan P Schneider, Fengmin Zhao, Molin Wang, et al.
Cancer|August 29, 2012
Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancerJoseph A Sparano, Molin Wang, Fengmin Zhao, et al.
JAMA Oncology|October 6, 2022
Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and MisinterpretationsFabio Conforti, Laura Pala, Vincenzo Bagnardi, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 2024
Cell cycle plasticity underlies fractional resistance to palbociclib in ER+/HER2- breast tumor cellsTarek M Zikry, Samuel C Wolff, Jolene S Ranek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2005
In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agentMichelle A Rudek, Ming Zhao, Nicola F Smith, et al.
Cancer|January 31, 2018
Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancerAnya Litvak, Bhavina Batukbhai, Stuart D Russell, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 10, 2021
Sociodemographic Factors Associated With Rapid Relapse in Triple-Negative Breast Cancer: A Multi-Institution StudySarah Asad, Carlos H Barcenas, Richard J Bleicher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2017
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused UpdateIan Krop, Nofisat Ismaila, Fabrice Andre, et al.
Human Pathology|January 22, 2014
A PIK3CA mutation detected in plasma from a patient with synchronous primary breast and lung cancersDanijela Jelovac, Julia A Beaver, Sasidharan Balukrishna, et al.
Pageof 84

Showing results (611-620 of 831) with videos related to

Sort By:
Pageof 84
Evidence-Based Practice in Child and Adolescent Mental Health|December 25, 2025
Informing Suicide Risk Assessment Practices of High-Risk Preteens: Qualitative Insights from Youth and CaregiversKatherine M Tezanos, Elizabeth K Reynolds, April R Highlander, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2012
Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancerBryan P Schneider, Fengmin Zhao, Molin Wang, et al.
Cancer|August 29, 2012
Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancerJoseph A Sparano, Molin Wang, Fengmin Zhao, et al.
JAMA Oncology|October 6, 2022
Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and MisinterpretationsFabio Conforti, Laura Pala, Vincenzo Bagnardi, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 2024
Cell cycle plasticity underlies fractional resistance to palbociclib in ER+/HER2- breast tumor cellsTarek M Zikry, Samuel C Wolff, Jolene S Ranek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2005
In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agentMichelle A Rudek, Ming Zhao, Nicola F Smith, et al.
Cancer|January 31, 2018
Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancerAnya Litvak, Bhavina Batukbhai, Stuart D Russell, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 10, 2021
Sociodemographic Factors Associated With Rapid Relapse in Triple-Negative Breast Cancer: A Multi-Institution StudySarah Asad, Carlos H Barcenas, Richard J Bleicher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2017
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused UpdateIan Krop, Nofisat Ismaila, Fabrice Andre, et al.
Human Pathology|January 22, 2014
A PIK3CA mutation detected in plasma from a patient with synchronous primary breast and lung cancersDanijela Jelovac, Julia A Beaver, Sasidharan Balukrishna, et al.
Pageof 84